Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crescent Biopharma Inc (CBIO)

Crescent Biopharma Inc (CBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 295,643
  • Shares Outstanding, K 13,893
  • Annual Sales, $ 10,840 K
  • Annual Income, $ -153,940 K
  • EBIT $ -163 M
  • EBITDA $ -163 M
  • 60-Month Beta 1.04
  • Price/Sales 24.92
  • Price/Cash Flow N/A
  • Price/Book 1.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.85
  • Number of Estimates 5
  • High Estimate $-0.67
  • Low Estimate $-0.99
  • Prior Year $-4.00
  • Growth Rate Est. (year over year) +78.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.27 +111.09%
on 03/24/26
22.22 -2.39%
on 04/20/26
+10.79 (+98.99%)
since 03/20/26
3-Month
8.72 +148.74%
on 02/09/26
22.22 -2.39%
on 04/20/26
+7.71 (+55.15%)
since 01/20/26
52-Week
8.72 +148.74%
on 02/09/26
28.77 -24.61%
on 05/05/25
-0.61 (-2.74%)
since 04/17/25

Most Recent Stories

More News
Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing...

CBIO : 21.69 (+1.93%)
Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing...

CBIO : 21.69 (+1.93%)
Crescent Biopharma: Q4 Earnings Snapshot

Crescent Biopharma: Q4 Earnings Snapshot

CBIO : 21.69 (+1.93%)
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical...

CBIO : 21.69 (+1.93%)
Crescent Biopharma to Present at March Investor Conferences

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing...

CBIO : 21.69 (+1.93%)
Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing...

CBIO : 21.69 (+1.93%)
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients...

CBIO : 21.69 (+1.93%)
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing...

CBIO : 21.69 (+1.93%)
Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing...

CBIO : 21.69 (+1.93%)
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept...

CBIO : 21.69 (+1.93%)

Business Summary

Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. Crescent Biopharma, formerly known as GlycoMimetics Inc., is based in ROCKVILLE, Md.

See More

Key Turning Points

3rd Resistance Point 23.97
2nd Resistance Point 23.10
1st Resistance Point 22.39
Last Price 21.69
1st Support Level 20.81
2nd Support Level 19.94
3rd Support Level 19.23

See More

52-Week High 28.77
Last Price 21.69
Fibonacci 61.8% 21.11
Fibonacci 50% 18.75
Fibonacci 38.2% 16.38
52-Week Low 8.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.